Ignite Creation Date:
2024-05-05 @ 11:41 AM
Last Modification Date:
2024-10-26 @ 9:11 AM
Study NCT ID:
NCT00101439
Status:
COMPLETED
Last Update Posted:
2024-06-18
First Post:
2005-01-10
Brief Title:
A Study to Evaluate the Effects of Ezetimibe MK-0653 on the Postprandial Following a Meal Lipoprotein Response in Participants With Primary Hypercholesterolemia High Cholesterol MK-0653-072COMPLETED
Sponsor:
Organon and Co
Organization:
Organon and Co
Study Overview
Official Title:
A Randomized Double-Blind Placebo-Controlled 2-Period Crossover Study to Evaluate the Effects of Ezetimibe on the Postprandial Lipoprotein Response in Patients With Primary Hypercholesterolemia
Status:
COMPLETED
Status Verified Date:
2022-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
A study to evaluate the cholesterol-lowering effects of ezetimibe in participants with primary hypercholesterolemia high cholesterol after eating a meal that is high in cholesterol The primary hypothesis is that treatment with ezetimibe 10 mgday reduces the cholesterol concentration of the chylomicron-containing Sf400 fraction following a cholesterol-enriched test meal
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 2005_001 | None | None | None |
| MK-0653-072 | None | None | None |